HEPA vs MDGL vs AKRO vs HIMS vs ELVN

For growth investors, Madrigal Pharmaceuticals, Inc.

(MDGL) is the stronger pick with 432. 1% revenue growth year-over-year, versus 59. 0% for Hims & Hers Health, Inc. (HIMS). Hims & Hers Health, Inc. (HIMS) offers the better valuation at 55. 4x trailing P/E (58. 3x forward), making it the more compelling value choice. Analysts rate Madrigal Pharmaceuticals, Inc. (MDGL) a "Buy" — based on 23 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Madrigal Pharmaceuticals, Inc.

(MDGL) delivered a total return of +286. 8%, compared to -100. 0% for Hepion Pharmaceuticals, Inc. (HEPA). Over 10 years, the gap is even starker: MDGL returned +37. 3% versus HEPA's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Hepion Pharmaceuticals, Inc.

(HEPA) is the lower-risk stock at -0. 91β versus Hims & Hers Health, Inc. 's 2. 48β — meaning HIMS is approximately -373% more volatile than HEPA relative to the S&P 500. On balance sheet safety, Hepion Pharmaceuticals, Inc. (HEPA) carries a lower debt/equity ratio of 2% versus 2% for Hims & Hers Health, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Madrigal Pharmaceuticals, Inc.

(MDGL) is pulling ahead at 432. 1% versus 59. 0% for Hims & Hers Health, Inc. (HIMS). On earnings-per-share growth, the picture is similar: Hepion Pharmaceuticals, Inc. grew EPS 99. 2% year-over-year, compared to -29. 8% for Akero Therapeutics, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Hims & Hers Health, Inc.

(HIMS) is the more profitable company, earning 5. 5% net margin versus -30. 1% for Madrigal Pharmaceuticals, Inc. — meaning it keeps 5. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HIMS leads at 5. 2% versus -31. 3% for MDGL. At the gross margin level — before operating expenses — MDGL leads at 94. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for ELVN: 44.

8% to $59. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Hepion Pharmaceuticals, Inc.

(HEPA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 91)). Hims & Hers Health, Inc. (HIMS) carries a higher beta of 2. 48 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (HEPA: -100. 0%, HIMS: +188. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: HEPA is a small-cap quality compounder stock; MDGL is a mid-cap high-growth stock; AKRO is a small-cap quality compounder stock; HIMS is a small-cap high-growth stock; ELVN is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.